S3.
VDR genotype or combined genotype | All melanoma patients (n=74) | 100% VDR-positive cells (n=12) | <100% VDR-positive cells (n=62) | OR (CI) 100% vs. < 100% VDR-positive | P=100% vs. < 100% VDR-positive | >20%a VDR-positive cells (n=36) | ≤20% VDR-positive cells (n=38) | OR (CI)>20%vs. ≤ 20% VDR-positive | P>20%vs. ≤ 20% VDR-positive | VDR absence (0% positive)(n=15) | VDR presence (>0% positive)(n=59) | OR (CI) VDR absence vs. presence | PVDR absence vs. presence |
FokI genotype | |||||||||||||
FF | 32 (43.2) | 5 (41.7) | 27 (43.5) | 0.93 (0.26–3.24) | 0.904 | 16 (44.4) | 16 (42.1) | 1.10 (0.44–2.76) | 0.839 | 7 (46.7) | 25 (42.4) | 1.19 (0.38–3.71) | 0.764 |
Ff | 33 (44.6) | 5 (41.7) | 28 (45.2) | 0.87 (0.25–3.03) | 0.824 | 14 (38.9) | 19 (50.0) | 0.64 (0.25–1.60) | 0.337 | 6 (40.0) | 27 (45.8) | 0.79 (0.25–2.50) | 0.688 |
ff | 9 (12.2) | 2 (16.7) | 7 (11.3) | 1.57 (0.28–8.69) | 0.633 | 6 (16.7) | 3 (7.9) | 2.33 (0.54–10.1) | 0.302 | 2 (13.3) | 7 (11.9) | 1.14 (0.21–6.16) | 1.000 |
F allele | 97/148 (65.5) | 15/24 (62.5) | 82/124 (66.1) | 0.85 (0.34–2.11) | 0.732 | 46/72 (63.9) | 51/76 (67.1) | 0.87 (0.44–1.71) | 0.681 | 20/30 (66.7) | 77/118 (65.3) | 1.06 (0.46–2.49) | 0.884 |
f allele | 51/148 (34.5) | 9/24 (37.5) | 42/124 (33.9) | 1.17 (0.47–2.90 | 0.732 | 26/72 (36.1) | 25/76 (32.9) | 1.15 (0.58–2.27) | 0.681 | 10/30 (33.3) | 41/118 (34.7) | 0.94 (0.40–2.19) | 0.884 |
BsmI genotype | |||||||||||||
BB | 23 (31.1) | 5 (41.7) | 18 (29.0) | 1.75 (0.49–6.23) | 0.498 | 9 (25.0) | 14 (36.8) | 0.57 (0.21–1.56) | 0.271 | 6 (40.0) | 17 (28.8) | 1.65 (0.51–5.34) | 0.533 |
Bb | 38 (51.4) | 4 (33.3) | 34 (54.8) | 0.41 (0.11–1.51) | 0.172 | 22 (61.1) | 16 (42.1) | 2.16 (0.85–5.47) | 0.102 | 6 (40.0) | 32 (54.2) | 0.56 (0.18–1.78) | 0.325 |
bb | 13 (17.6) | 3 (25.0) | 10 (16.1) | 1.73 (0.40–7.55) | 0.432 | 5 (13.9) | 8 (21.1) | 0.60 (0.18–2.06) | 0.418 | 3 (20.0) | 10 (16.9) | 1.22 (0.29–5.15) | 0.719 |
Continued |